I never realized we were competing with PFE and it appears they are leading the race from their announcement last week. Would love to hear some discussion on this topic during the cc this week. Did I miss this or were we never told of the competition and is it really competition as it appears to be?
I am excited about the Hopkins collaboration but share your concern regarding conflict with the principal collaborators at JH. Both Drs. Pardell and.Drake were founders of Amplimmune, which was bought by Medimmune for $220 and there are still outstanding potential royalties of $270 m for ongoing product development of B-7 molecules. One question is whether Drs. Drew and Pardoll would share in any Amplimmune royalties? If so, It would be helpful if CGEN management explained whether the Amplimmune B-7 products will potentially compete with the CGEN products under development, and what measures are in place to prevent potential conflicts for the JH team if working on both companies' products and particularly the timing of advancing the CGEN products?